<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1156" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1156/" /><meta name="ncbi_pagename" content="Camurati-Engelmann Disease - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Camurati-Engelmann Disease - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Camurati-Engelmann Disease" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/10/12" /><meta name="citation_author" content="Stephanie E Wallace" /><meta name="citation_author" content="William R Wilcox" /><meta name="citation_pmid" content="20301335" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1156/" /><meta name="citation_keywords" content="Progressive Diaphyseal Dysplasia" /><meta name="citation_keywords" content="Progressive Diaphyseal Dysplasia" /><meta name="citation_keywords" content="Ribbing Disease" /><meta name="citation_keywords" content="Transforming growth factor beta-1 proprotein" /><meta name="citation_keywords" content="TGFB1" /><meta name="citation_keywords" content="Camurati-Engelmann Disease" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Camurati-Engelmann Disease" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Stephanie E Wallace" /><meta name="DC.Contributor" content="William R Wilcox" /><meta name="DC.Date" content="2017/10/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1156/" /><meta name="description" content="Camurati-Engelmann disease (CED) is characterized by hyperostosis of the long bones and the skull, proximal muscle weakness, limb pain, a wide-based, waddling gait, and joint contractures. Facial features such as macrocephaly, frontal bossing, enlargement of the mandible, proptosis, and cranial nerve impingement resulting in facial palsy are seen in severely affected individuals later in life." /><meta name="og:title" content="Camurati-Engelmann Disease" /><meta name="og:type" content="book" /><meta name="og:description" content="Camurati-Engelmann disease (CED) is characterized by hyperostosis of the long bones and the skull, proximal muscle weakness, limb pain, a wide-based, waddling gait, and joint contractures. Facial features such as macrocephaly, frontal bossing, enlargement of the mandible, proptosis, and cranial nerve impingement resulting in facial palsy are seen in severely affected individuals later in life." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1156/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ced/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1156/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE894EF1E040A5210000000002D70150.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1156_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1156_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/campo-dysp/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/canavan/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1156_"><span class="title" itemprop="name">Camurati-Engelmann Disease</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Progressive Diaphyseal Dysplasia</div><p class="contrib-group"><span itemprop="author">Stephanie E Wallace</span>, MD and <span itemprop="author">William R Wilcox</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1156_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1156_ai__"><div class="contrib half_rhythm"><span itemprop="author">Stephanie E Wallace</span>, MD<div class="affiliation small">Division of Genetic Medicine<br />University of Washington<br />Seattle Children&#x02019;s Hospital<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.snerdlihcelttaes@ecallaw.einahpets" class="oemail">gro.snerdlihcelttaes@ecallaw.einahpets</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">William R Wilcox</span>, MD, PhD<div class="affiliation small">Department of Human Genetics<br />Emory University School of Medicine<br />Atlanta, Georgia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.yrome@xocliw.mailliw" class="oemail">ude.yrome@xocliw.mailliw</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 25, 2004</span>; Last Update: <span itemprop="dateModified">October 12, 2017</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ced.Summary" itemprop="description"><h2 id="_ced_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Camurati-Engelmann disease (CED) is characterized by hyperostosis of the long bones and the skull, proximal muscle weakness, limb pain, a wide-based, waddling gait, and joint contractures. Facial features such as macrocephaly, frontal bossing, enlargement of the mandible, proptosis, and cranial nerve impingement resulting in facial palsy are seen in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals later in life.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of CED is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the characteristic radiographic findings or on identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TGFB1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if radiographic findings are inconclusive.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Corticosteroid therapy as needed to control symptoms; losartan may be a helpful adjuvant therapy to minimize the need for steroids to control pain. Pain is also managed with analgesics and non-pharmacologic methods. Craniectomy may be needed to reduce intracranial pressure and relieve symptoms in individuals with several cranial sclerosis. Bilateral myringotomy can improve conductive hearing loss resulting from serous otitis.</p><p><i>Prevention of secondary complications:</i> Monitor blood pressure in individuals treated with corticosteroids and treat hypertension if necessary; individuals taking losartan also need regular blood pressure monitoring due to the increased risk for hypotension; taper corticosteroid dose as tolerated to reduce the risk of osteoporosis and compression fractures of the spine.</p><p><i>Surveillance:</i> Following initiation of corticosteroid treatment, blood pressure should be monitored monthly; when maintenance steroid dose is achieved, yearly evaluation includes complete neurologic examination, CBC, blood pressure, audiology evaluation, ophthalmology evaluation, and bone density scan; routine monitoring of linear growth in children due to the possible side effect of delayed or stunted growth; individuals with cranial hyperostosis (including those treated surgically) should continue to be monitored for signs and symptoms of increased intracranial pressure.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>CED is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Penetrance is reduced. The incidence of <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown. Each child of an individual with CED has a 50% chance of inheriting the <i>TGFB1</i> pathogenic variant. Prenatal testing and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for pregnancies at increased risk are possible options for families in which the pathogenic variant has been identified.</p></div></div><div id="ced.GeneReview_Scope"><h2 id="_ced_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="ced.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1156/table/ced.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ced.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ced.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Camurati-Engelmann Disease: Included Phenotype</th></tr></thead><tbody><tr><td headers="hd_h_ced.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ribbing disease</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#ced.Nomenclature">Nomenclature</a>.</p></div></dd></dl></div></div></div></div><div id="ced.Diagnosis"><h2 id="_ced_Diagnosis_">Diagnosis</h2><p>There are no current published guidelines for the diagnosis of Camurati-Engelmann disease.</p><div id="ced.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Camurati-Engelmann disease (CED) <b>should be suspected</b> in individuals with the following clinical findings:</p><ul><li class="half_rhythm"><div>Proximal muscle weakness</div></li><li class="half_rhythm"><div>Limb pain</div></li><li class="half_rhythm"><div>Waddling gait</div></li></ul></div><div id="ced.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of CED <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the characteristic radiographic findings or, if radiographic findings are inconclusive, on identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TGFB1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK1156/table/ced.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figcedTmoleculargenetictestingusedin" rid-ob="figobcedTmoleculargenetictestingusedin">Table 1</a>).</p><p><b>Radiographic findings</b></p><ul><li class="half_rhythm"><div>Hyperostosis of one or more of the long bones:</div><ul><li class="half_rhythm"><div>Begins with the diaphyses of the long bones</div></li><li class="half_rhythm"><div>Can progress to the metaphyses and (in rare cases) epiphyses</div></li></ul></li><li class="half_rhythm"><div>Periosteal involvement with uneven cortical thickening and increased diameter</div></li><li class="half_rhythm"><div>Endosteal bony sclerosis that can lead to narrowed medullary canal</div></li><li class="half_rhythm"><div>Hyperostosis usually symmetric in the appendicular skeleton but in some cases asymmetric</div><div>Note: Hyperostosis does not affect the spine.</div></li><li class="half_rhythm"><div>Other radiologic findings variably seen:</div><ul><li class="half_rhythm"><div>Skull involvement beginning at the base of the anterior and middle fossae and often including the frontal bone [<a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>]</div></li><li class="half_rhythm"><div>Mild osteosclerosis in the posterior neural arch of the spine and parts of the flat bones that correspond to the diaphysis</div></li></ul></li></ul><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>TGFB1</i> is performed<i>.</i></div><div class="half_rhythm">Note: CED is postulated to occur through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism. Large intragenic deletions or duplications have not been reported in individuals with CED; testing for intragenic deletions or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> is not indicated.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>TGFB1</i> and other genes of interest (see <a href="#ced.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> varies by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="ced.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Camurati-Engelmann Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1156/table/ced.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ced.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TGFB1</i></td><td headers="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td><td headers="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_ced.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ced.TF.1.1"><p class="no_margin">See <a href="/books/NBK1156/#ced.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ced.TF.1.2"><p class="no_margin">See <a href="#ced.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ced.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="ced.TF.1.4"><p class="no_margin">The majority are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 leading to single amino acid substitutions in the encoded protein [<a class="bk_pop" href="#ced.REF.janssens.2000.273">Janssens et al 2000</a>, <a class="bk_pop" href="#ced.REF.kinoshita.2000.19">Kinoshita et al 2000</a>, <a class="bk_pop" href="#ced.REF.camposxavier.2001.653">Campos-Xavier et al 2001</a>, <a class="bk_pop" href="#ced.REF.hecht.2001.198">Hecht et al 2001</a>, <a class="bk_pop" href="#ced.REF.mumm.2001.593">Mumm et al 2001</a>, <a class="bk_pop" href="#ced.REF.janssens.2003.7718">Janssens et al 2003</a>, <a class="bk_pop" href="#ced.REF.kinoshita.2004.104">Kinoshita et al 2004</a>, <a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>, <a class="bk_pop" href="#ced.REF.janssens.2006.1">Janssens et al 2006</a>].</p></div></dd><dt>5. </dt><dd><div id="ced.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="ced.TF.1.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>7. </dt><dd><div id="ced.TF.1.7"><p class="no_margin">The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> members of one family with CED did not share marker haplotypes at the TGFB1 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and had no sequence alterations in <i>TGFB1</i> exons 1 through 7; <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> was not done on these individuals [<a class="bk_pop" href="#ced.REF.hecht.2001.198">Hecht et al 2001</a>]. Several additional individuals with CED have not had <i>TGFB1</i> pathogenic variants identified, implying genetic locus heterogeneity [Author, personal observation].</p></div></dd></dl></div></div></div></div></div><div id="ced.Clinical_Characteristics"><h2 id="_ced_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ced.Clinical_Description"><h3>Clinical Description</h3><p>Individuals with Camurati-Engelmann disease (CED) present with limb pain, proximal muscle weakness, poor muscular development, a wide-based, waddling gait, easy fatigability, and headaches. The average age of onset of symptoms in the 306 reported individuals is 13.4 years [<a class="bk_pop" href="#ced.REF.carlson.2010.566">Carlson et al 2010</a>] with a range from birth to age 76 years [<a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>].</p><p><b>Musculoskeletal.</b> Decreased muscle mass and weakness are most apparent in the proximal lower limbs, resulting in difficulty when rising from a sitting position. A wide-based, waddling gait is found in 48%-64% of individuals. Joint contractures occur in 43% of individuals. Marfanoid body habitus is described in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>, <a class="bk_pop" href="#ced.REF.janssens.2006.1">Janssens et al 2006</a>]. Musculoskeletal involvement can lead to varying degrees of lumbar lordosis, kyphosis, scoliosis, coxae valga, radial head dislocation, genua valga, hallux valgus, flat feet, and frontal bossing [<a class="bk_pop" href="#ced.REF.yuldashev.2017.109">Yuldashev et al 2017</a>].</p><p>Bone pain is reported in 68%-90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>, <a class="bk_pop" href="#ced.REF.janssens.2006.1">Janssens et al 2006</a>]. The reported severity of bone pain ranged from mild (not requiring any treatment) to severe (requiring narcotic analgesics) [<a class="bk_pop" href="#ced.REF.yuldashev.2017.109">Yuldashev et al 2017</a>]. The pain is described as constant, aching, and most intense in the lower limbs. Pain often increases with activity, stress, and cold weather. Many individuals have intermittent episodes of severe pain and incapacitation. Bone pain has resulted in limited ambulation in some individuals. The enlarged bone shafts can also be palpable and tender on examination; 52% of affected individuals report bone tenderness with palpation [<a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>]. Intermittent limb swelling, erythema, and warmth also occur.</p><p>Although bone mineral density measured at the hip and femoral neck are increased in individuals with CED, bone strength measured by bone impact microindentation in three sibs with CED was below normal. Because of the small sample size, the difference in bone strength was not statistically significant. [<a class="bk_pop" href="#ced.REF.herrera.2017.3489">Herrera et al 2017</a>]. Increased susceptibility to fracture has not been reported. Healing of fractures, when they occur, may be delayed [<a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>].</p><p><b>Neurologic.</b> Sclerosis of the cranial nerve foramina can lead to direct nerve compression or neurovascular compromise. Cranial nerve deficits occur in 38% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. The most common deficits are hearing loss, vision problems, and facial paralysis.</p><p>Approximately 19% of individuals with CED have conductive and/or sensorineural hearing loss [<a class="bk_pop" href="#ced.REF.carlson.2010.566">Carlson et al 2010</a>]. Conductive loss can be caused by narrowing of the external auditory meatus, bony encroachment of the ossicles, or narrowing of the oval and round windows. Sensorineural hearing loss is caused by narrowing of the internal auditory canal and compression of the cochlear nerve and/or vasculature. Sensorineural hearing loss can also occur with attempted decompression of the facial nerves.</p><p>Involvement of the orbit has led to blurred vision, proptosis, papilledema, epiphora, glaucoma, and subluxation of the globe [<a class="bk_pop" href="#ced.REF.carlson.2010.566">Carlson et al 2010</a>, <a class="bk_pop" href="#ced.REF.popiela.2015">Popiela &#x00026; Austin 2015</a>].</p><p>Rarely, clonus [<a class="bk_pop" href="#ced.REF.neuhauser.1948.11">Neuhauser et al 1948</a>], sensory loss, slurred speech, dysphagia, cerebellar ataxia, and bowel and bladder incontinence are reported [<a class="bk_pop" href="#ced.REF.carlson.2010.566">Carlson et al 2010</a>]. Calvarial hyperostosis can lead to increased intracranial pressure and headaches.</p><p>Recurrent cranial hyperostosis following surgical decompression can occur [<a class="bk_pop" href="#ced.REF.wong.2017.555">Wong et al 2017</a>].</p><p><b>Facial features.</b> Children with CED do not typically have recognizable changes to their facial features. In older individuals who are severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, osteosclerosis of the skull can lead to macrocephaly, frontal bossing, enlargement of the mandible, proptosis, and cranial nerve impingement resulting in facial palsy.</p><p><b>Ribbing disease,</b> an osteosclerotic disease of the long bones that is radiographically indistinguishable from CED and usually presents with bone pain after puberty [<a class="bk_pop" href="#ced.REF.makita.2000.153">Makita et al 2000</a>], is now known to be caused by pathogenic variants in <i>TGFB1</i> [<a class="bk_pop" href="#ced.REF.janssens.2006.1">Janssens et al 2006</a>]. Thus, CED and Ribbing disease represent phenotypic variations of the same disorder.</p><p><b>Other.</b> Rare manifestations include anemia (hypothesized to be caused by a narrowed medullary cavity), anorexia, low body mass index, hepatosplenomegaly, decreased subcutaneous tissue, atrophic skin, hyperhidrosis of the hands and feet, delayed dentition, extensive caries, delayed puberty, and hypogonadism [<a class="bk_pop" href="#ced.REF.gupta.2005.399">Gupta &#x00026; Cheikh 2005</a>, <a class="bk_pop" href="#ced.REF.yuldashev.2017.109">Yuldashev et al 2017</a>].</p><p><b>Pregnancy.</b> One individual who experienced relief with steroids also experienced decreased bone pain and improved muscle strength while pregnant, which allowed discontinuation of her steroid therapy. Scintigraphic bone imaging with methylene diphosphate (MDP) a few hours after delivery of her second child showed decreased uptake compared to imaging prior to pregnancy and six weeks post partum.</p></div><div id="ced.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No known correlation exists between the nature of the <i>TGFB1</i> pathogenic variants and the severity of the clinical or radiographic manifestations [<a class="bk_pop" href="#ced.REF.camposxavier.2001.653">Campos-Xavier et al 2001</a>].</p></div><div id="ced.Penetrance"><h3>Penetrance</h3><p>Some obligate heterozygotes with an identified <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have had normal radiographs [<a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>]; an exact <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> figure is not known.</p></div><div id="ced.Anticipation"><h3>Anticipation</h3><p>Earlier onset of symptoms and increased severity of symptoms and bone involvement in successive generations has been reported in several families [<a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>, <a class="bk_pop" href="#ced.REF.janssens.2006.1">Janssens et al 2006</a>]. If these findings represent <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> rather than ascertainment bias (the latter being more likely), the mechanism of anticipation is unknown. Although multiple copies of the amino acid leucine can be encoded by one observed <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1, the pathogenic variant was not found in these families.</p></div><div id="ced.Nomenclature"><h3>Nomenclature</h3><p>Engelmann described the second reported occurrence of CED in 1929 as "osteopathic hyperostotica (sclerotisans) multiplex infantilis."</p><p>The terms Engelmann disease and diaphyseal dysplasia were commonly used until <a class="bk_pop" href="#ced.REF.neuhauser.1948.11">Neuhauser et al [1948]</a> coined the term progressive diaphyseal dysplasia.</p><p><a class="bk_pop" href="#ced.REF.gulledge.1951.793">Gulledge &#x00026; White [1951]</a> suggested the term progressive diaphyseal hyperostosis, which was not widely used.</p></div><div id="ced.Prevalence"><h3>Prevalence</h3><p>The prevalence is unknown. More than 300 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been reported.</p><p>The disorder is pan ethnic.</p></div></div><div id="ced.Genetically_Related_Allelic_Disorder"><h2 id="_ced_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>TGFB1.</i></p></div><div id="ced.Differential_Diagnosis"><h2 id="_ced_Differential_Diagnosis_">Differential Diagnosis</h2><p>Few disorders share the clinical and radiographic findings of Camurati-Engelmann disease (CED). The correct diagnosis is made by physical examination and skeletal survey.</p><div id="ced.T.disorders_to_consider_in_the_diffe" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of CED</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1156/table/ced.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ced.T.disorders_to_consider_in_the_diffe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_1" style="text-align:left;vertical-align:middle;">Differential Diagnosis Disorder</th><th id="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/CED</th><th headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from CED</th></tr></thead><tbody><tr><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Craniodiaphyseal dysplasia (CDD) (OMIM <a href="http://omim.org/entry/218300" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">218300</a>)</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR (suggested)</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diaphyseal sclerosis, cranial hyperostosis</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cranial involvement in CED is milder &#x00026; rarely results in frontal bossing &#x00026; proptosis.</div></li><li class="half_rhythm"><div>The sclerosis of the long bones in CDD is restricted to the diaphyses; in CED metaphyses can also be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul>
</td></tr><tr><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Kenny-Caffey syndrome type 2 (OMIM <a href="http://omim.org/entry/127000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">127000</a>)</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FAM111A</i></td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sclerosis of long bones, cortical thickening, medullary stenosis</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypocalcemia, hypoparathyroidism, delayed fontanelle closure</td></tr><tr><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Juvenile Paget disease (OMIM <a href="http://omim.org/entry/239000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">239000</a>)</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TNFRSF11B</i></td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cranial hyperostosis, sensorineural hearing loss, sclerosis of long bones</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predisposition to fractures, bowing of the long bones</td></tr><tr><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ghosal hematodiaphyseal dysplasia (OMIM <a href="http://omim.org/entry/231095" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231095</a>)</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TBXAS1</i></td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diaphyseal sclerosis</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe anemia; leukopenia &#x00026; thrombocytopenia</td></tr><tr><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Endosteal hyperostosis, AD (OMIM <a href="http://omim.org/entry/144750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">144750</a>)</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LRP5</i></td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diaphyseal sclerosis (endosteal), cranial nerve involvement in some</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Wide deep mandible w/&#x02191; gonial angle (distinct from the enlarged mandible found only occasionally in CED)</td></tr><tr><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sost/"><i>SOST</i>-related sclerosing bone dysplasias</a> incl sclerosteosis &#x00026; van Buchem disease</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SOST</i></td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cranial hyperostosis, cranial nerve involvement, diaphyseal sclerosis</td><td headers="hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_ced.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Syndactyly, dysplastic or absent nails</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd></dl></div></div></div></div><div id="ced.Management"><h2 id="_ced_Management_">Management</h2><div id="ced.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Camurati-Engelmann disease (CED), the initial evaluation should include the following if they have not already been completed:</p><ul><li class="half_rhythm"><div>Complete skeletal survey</div></li><li class="half_rhythm"><div>Assessment for cranial nerve deficits, including neurologic examination, audiology evaluation, and ophthalmologic evaluation</div></li><li class="half_rhythm"><div>Baseline blood pressure if considering treatment with losartan</div></li><li class="half_rhythm"><div>CBC to evaluate for anemia in individuals with significant endosteal involvement</div></li><li class="half_rhythm"><div>If acute bone pain is present, consideration of serum ESR and bone scan examination as baseline measures of disease activity</div></li><li class="half_rhythm"><div>In individuals with radiographic evidence of skull base sclerosis and neurologic symptoms, consideration of baseline CT examination of the head and neck to determine the extent of disease and allow consideration of surgical treatment options</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="ced.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>No consensus management guidelines have been developed to date.</p><p><b>Corticosteroids</b> may relieve many of the symptoms of Camurati-Engelmann disease (CED). Several investigators report success with corticosteroid treatment in reducing pain and weakness; improving gait, exercise tolerance, and flexion contractures; and correcting anemia and hepatosplenomegaly [<a class="bk_pop" href="#ced.REF.lindstrom.1974.504">Lindstrom 1974</a>, <a class="bk_pop" href="#ced.REF.ba_.1999.401">Ba&#x0015f; et al 1999</a>, <a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>]. Unsuccessful steroid therapy was reported in one adult.</p><p>Individuals with severe symptoms can be treated with a bolus of prednisolone 1.0-2.0 mg/kg/day followed by rapid tapering to the lowest alternate-day dose tolerated. Less symptomatic individuals can be started on 0.5-1.0 mg/kg every other day. Some individuals may be able to discontinue steroid therapy during quiescent periods.</p><p>Higher-dose steroids may help with acute pain crises.</p><p>Note: Steroids may delay bone hyperostosis and prevent or delay the onset of skull involvement. Although histologic studies following steroid therapy showed increased bone resorption and secondary remodeling with increased osteoblast activity and decreased lamellar bone deposition, several authors reported no regression of sclerosis on radiographic evaluation [<a class="bk_pop" href="#ced.REF.verbruggen.1985.809">Verbruggen et al 1985</a>] or on scintigraphic evaluation [<a class="bk_pop" href="#ced.REF.ba_.1999.401">Ba&#x0015f; et al 1999</a>]. <a class="bk_pop" href="#ced.REF.lindstrom.1974.504">Lindstrom [1974]</a> and <a class="bk_pop" href="#ced.REF.ba_.1999.401">Ba&#x0015f; et al [1999]</a> reported diminished sclerosis on radiographs following steroid therapy. <a class="bk_pop" href="#ced.REF.verbruggen.1985.809">Verbruggen et al [1985]</a> and <a class="bk_pop" href="#ced.REF.inaoka.2001.680">Inaoka et al [2001]</a> reported reduced radioactivity on bone scintigraphy. Long-term follow-up studies should be conducted to evaluate the success of corticosteroid therapy in preventing anemia, hepatosplenomegaly, headaches, and cranial nerve impingement.</p><p><b>Calcitonin.</b> Pain relief from intranasal calcitonin was reported in one individual [<a class="bk_pop" href="#ced.REF.trombetti.2012.75">Trombetti et al 2012</a>].</p><p><b>Losartan.</b> Reduced bone pain and increased physical activity were reported in two individuals treated with losartan [<a class="bk_pop" href="#ced.REF.ayyavoo.2014.3978">Ayyavoo et al 2014</a>, <a class="bk_pop" href="#ced.REF.simsekkiper.2014.2667">Simsek-Kiper et al 2014</a>]. Losartan has an anti-TGF&#x003b2; effect and is being tested in individuals with <a href="/books/n/gene/marfan/">Marfan syndrome</a>. Treatment with losartan has not improved bone pain in some individuals [<a class="bk_pop" href="#ced.REF.yuldashev.2017.109">Yuldashev et al 2017</a>]</p><p><b>Other</b> analgesics and non-pharmacologic methods are frequently used for alleviation of pain.</p><p><b>Surgical</b> treatment for persistent bone pain by intramedullary reaming was reported in a woman age 22 years diagnosed with Ribbing disease [<a class="bk_pop" href="#ced.REF.ozt_rkmen.2011.58">Ozt&#x000fc;rkmen &#x00026; Karamehmeto&#x0011f;lu 2011</a>]. Pain in the tibia resolved completely following the surgery; the individual remained pain free at five-year follow up.</p><p>Craniectomy has relieved increased intracranial pressure and headaches in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#ced.REF.carlson.2010.566">Carlson et al 2010</a>]. Recurrent cranial hyperostosis with resultant increased intracranial pressure has been managed by radical craniectomy with titanium mesh cranioplasties [<a class="bk_pop" href="#ced.REF.wong.2017.555">Wong et al 2017</a>].</p><p><b>Hearing loss</b> evaluation by an otolaryngologist should include a BAER and a CT with fine cuts through the inner ear. Reports of successful treatment of hearing loss in CED are rare. Surgical decompression of the internal auditory canals can improve hearing. However, the skull hyperostosis is progressive, and cranial nerve compression often recurs.</p><p>Corticosteroids may delay skull hyperostosis and cranial nerve impingement. <a class="bk_pop" href="#ced.REF.lindstrom.1974.504">Lindstrom [1974]</a> reported no change in conductive hearing loss with steroid therapy. A woman age 30 years with a 75-dB neurosensory hearing loss on the right and a 65-dB neurosensory hearing loss of the left experienced some improvement in hearing with prednisone. Her hearing stabilized after decompression of the right internal auditory canal.</p><p>Bilateral myringotomy can improve conductive hearing loss resulting from serous otitis in individuals with CED.</p><p>A woman age 71 years with bilateral conductive hearing loss and patent internal auditory canals underwent a cochlear implantation, and speech detection improved from 75 dB to 45 dB [<a class="bk_pop" href="#ced.REF.friedland.2000.160">Friedland et al 2000</a>]. General contraindications for cochlear implants include a narrowed internal auditory canal and absence of a functioning eighth nerve, both of which can be found in individuals with CED.</p><p><a class="bk_pop" href="#ced.REF.carlson.2010.566">Carlson et al [2010]</a> reported six individuals with CED and bilateral sensorineural hearing loss. Three underwent internal auditory canal decompression with mixed results. Conservative management was used in the other three individuals with no worsening of symptoms (see also <a href="/books/n/gene/deafness-overview/">Hereditary Deafness and Hearing Loss Overview</a>).</p></div><div id="ced.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Initiation of steroids prior to the onset of proximal muscle weakness and/or sclerotic bone changes has not been reported. Because of the variable symptomatology and decreased <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, treatment of asymptomatic individuals cannot be recommended.</p></div><div id="ced.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Monitor blood pressure in individuals treated with corticosteroids and treat hypertension if necessary.</p><p>Individuals taking losartan also need regular blood pressure monitoring due to the increased risk for hypotension.</p><p>Taper corticosteroid dose as tolerated to reduce the risk of osteoporosis and compression fractures of the spine.</p></div><div id="ced.Surveillance"><h3>Surveillance</h3><p>After initiating corticosteroids, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals should be followed monthly, with efforts to taper the steroids to the lowest tolerated dose. Blood pressure should be monitored at each visit, as hypertension can develop following the initiation of steroid therapy.</p><p>When a maintenance steroid dose is achieved, ongoing evaluations should include the following:</p><ul><li class="half_rhythm"><div>Annual:</div><ul><li class="half_rhythm"><div class="half_rhythm">Complete neurologic examination</div></li><li class="half_rhythm"><div class="half_rhythm">CBC</div></li><li class="half_rhythm"><div class="half_rhythm">Measurement of blood pressure</div></li><li class="half_rhythm"><div class="half_rhythm">Audiology evaluation</div></li><li class="half_rhythm"><div class="half_rhythm">Ophthalmology evaluation</div></li><li class="half_rhythm"><div class="half_rhythm">Evaluation of bone mineral density</div><div class="half_rhythm">Note: CED does not appear to cause an increase in spine density; therefore, steroid therapy could lead to osteoporosis of the spine [Author, personal observation].</div></li></ul></li><li class="half_rhythm"><div>Routine monitoring of linear growth in children due to the possible side effect of delayed or stunted growth</div></li><li class="half_rhythm"><div>Individuals with cranial hyperostosis (including those treated surgically) should continue to be monitored for signs and symptoms of increased intracranial pressure, as cranial hyperostosis can recur.</div></li></ul><p>The authors are aware of one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> teenage individual who died of a dilated ascending aorta dissection. Whether this is related to CED is unknown. Because the mechanism of CED involves increased TGFB1 signaling, also found in <a href="/books/n/gene/marfan/">Marfan syndrome</a> and <a href="/books/n/gene/loeys-dietz/">Loeys-Dietz syndrome</a>, this death is of some concern. The authors are unaware of any other similar cases. Note: No recommendations for routine evaluation of the aorta can be made at this time.</p></div><div id="ced.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Bisphosphonates.</b> Pamidronate did not improve symptoms in four individuals [<a class="bk_pop" href="#ced.REF.inaoka.2001.680">Inaoka et al 2001</a>, <a class="bk_pop" href="#ced.REF.janssens.2006.1">Janssens et al 2006</a>]. Clodronate infusion caused increased bone pain in one individual with CED and no improvement in another individual reported by <a class="bk_pop" href="#ced.REF.castro.2005.398">Castro et al [2005]</a>.</p><p><b>Excess phosphate.</b> Treatment with cellulose phosphate led to worsening hypocalcemia and proximal myopathy in another individual.</p></div><div id="ced.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate relatives at risk in order to identify the diagnosis as early as possible, avoid potential misdiagnosis, and provide appropriate treatment for extremity pain.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known;</div></li><li class="half_rhythm"><div>Radiographic evaluation for hyperostosis if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known.</div></li></ul><p>See <a href="#ced.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ced.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="ced.Genetic_Counseling"><h2 id="_ced_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ced.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Camurati-Engelmann disease (CED) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="ced.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">Many individuals diagnosed with CED have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div class="half_rhythm">Some individuals diagnosed with CED may have the disorder as the result of a <i>de nov</i>o <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is unknown.</div></li><li class="half_rhythm"><div class="half_rhythm">Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div><div class="half_rhythm">If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</div></li><li class="half_rhythm"><div class="half_rhythm">The family history of some individuals diagnosed with CED may appear to be negative because of failure to recognize the disorder in family members, early death of a parent before the onset of symptoms, or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate evaluations (i.e., <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> or radiographs) have been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">Note: Though not reported, if the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 50%. However, the risk that sibs would be affected is less than 50% because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Severity is impossible to predict, as there is significant phenotypic variability within families.</div></li><li class="half_rhythm"><div>If the parents have been tested for the <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and:</div><ul><li class="half_rhythm"><div>A parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%. Because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, some individuals who inherit <i>TGFB1</i> pathogenic variants will not have manifestations. The exact penetrance is unknown.</div></li><li class="half_rhythm"><div>The <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the empiric <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is approximately 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul></li><li class="half_rhythm"><div>If the parents have not been tested for the <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low. The sibs of a proband with clinically unaffected parents are still at increased risk for CED because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or the theoretic possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with CED has a 50% chance of inheriting the <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="ced.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ced.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with CED has the <i>TGFB1</i> pathogenic variant or clinical evidence of the disorder, the <i>TGFB1</i> variant is likely <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ced.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>TGFB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for CED are possible.</p><p>Because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, results of prenatal testing may not be useful in accurately predicting age of onset, severity, type of symptoms, or rate of progression.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="ced.Resources"><h2 id="_ced_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Society for Deaf Children (ASDC)</b></div><div>800 Florida Avenue Northeast</div><div>Suite 2047</div><div>Washington DC 20002-3695</div><div><b>Phone:</b> 800-942-2732 (Toll-free Parent Hotline); 866-895-4206 (toll free voice/TTY)</div><div><b>Fax:</b> 410-795-0965</div><div><b>Email:</b> info@deafchildren.org; asdc@deafchildren.org</div><div><a href="http://www.deafchildren.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.deafchildren.org</a></div></li><li class="half_rhythm"><div><b>Face Equality International</b></div><div>United Kingdom</div><div><b>Email:</b> info@faceequalityinternational.org</div><div><a href="https://faceequalityinternational.org/thealliance/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.faceequalityinternational.org</a></div></li><li class="half_rhythm"><div><b>National Association of the Deaf (NAD)</b></div><div>8630 Fenton Street</div><div>Suite 820</div><div>Silver Spring MD 20910</div><div><b>Phone:</b> 301-587-1788; 301-587-1789 (TTY)</div><div><b>Fax:</b> 301-587-1791</div><div><b>Email:</b> nad.info@nad.org</div><div><a href="http://www.nad.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nad.org</a></div></li><li class="half_rhythm"><div><b>International Skeletal Dysplasia Registry</b></div><div>UCLA</div><div>615 Charles E. Young Drive</div><div>South Room 410</div><div>Los Angeles CA 90095-7358</div><div><b>Phone:</b> 310-825-8998</div><div><b>Fax:</b> 310-206-5266</div><div><b>Email:</b> Salon@mednet.ucla.edu</div><div><a href="https://www.uclahealth.org/ortho/isdr" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Skeletal Dysplasia Registry</a></div></li></ul></div><div id="ced.Molecular_Genetics"><h2 id="_ced_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ced.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Camurati-Engelmann Disease: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1156/table/ced.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ced.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ced.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ced.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ced.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ced.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ced.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ced.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ced.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7040" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TGFB1</i></a></td><td headers="hd_b_ced.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7040" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ced.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P01137" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Transforming growth factor beta-1 proprotein</a></td><td headers="hd_b_ced.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/TGFB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TGFB1 homepage</a><br /><a href="http://proteomics.bio21.unimelb.edu.au/lovd/genes/TGFB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TGFB1 homepage - LOVD Australian Human Variome Project</a></td><td headers="hd_b_ced.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TGFB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TGFB1</a></td><td headers="hd_b_ced.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TGFB1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TGFB1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ced.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ced.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Camurati-Engelmann Disease (<a href="/omim/131300,190180,601477" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1156/table/ced.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ced.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/131300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">131300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAMURATI-ENGELMANN DISEASE; CAEND</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/190180" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">190180</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TRANSFORMING GROWTH FACTOR, BETA-1; TGFB1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601477" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601477</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RIBBING DISEASE</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>TGFB1</i> has seven exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1156/#ced.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Three pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 of <i>TGFB1</i> account for approximately 80% of the pathogenic variants observed in CED [<a class="bk_pop" href="#ced.REF.janssens.2000.273">Janssens et al 2000</a>, <a class="bk_pop" href="#ced.REF.kinoshita.2000.19">Kinoshita et al 2000</a>, <a class="bk_pop" href="#ced.REF.camposxavier.2001.653">Campos-Xavier et al 2001</a>, <a class="bk_pop" href="#ced.REF.hecht.2001.198">Hecht et al 2001</a>, <a class="bk_pop" href="#ced.REF.mumm.2001.593">Mumm et al 2001</a>, <a class="bk_pop" href="#ced.REF.janssens.2003.7718">Janssens et al 2003</a>, <a class="bk_pop" href="#ced.REF.kinoshita.2004.104">Kinoshita et al 2004</a>, <a class="bk_pop" href="#ced.REF.wallace.2004.235">Wallace et al 2004</a>, <a class="bk_pop" href="#ced.REF.janssens.2006.1">Janssens et al 2006</a>]:</p><ul><li class="half_rhythm"><div>c.652C&#x0003e;T is found in about 40% of individuals.</div></li><li class="half_rhythm"><div>c.653G&#x0003e;A or c.673T&#x0003e;C is found in an additional 35% of individuals.</div></li><li class="half_rhythm"><div>Other selected pathogenic variants are listed in <a class="figpopup" href="/books/NBK1156/table/ced.T.tgfb1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figcedTtgfb1pathogenicvariantsdiscusse" rid-ob="figobcedTtgfb1pathogenicvariantsdiscusse">Table 3</a>.</div></li></ul><p>For more information, see <a href="/books/NBK1156/#ced.molgen.TA">Table A</a>.</p><div id="ced.T.tgfb1_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>TGFB1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1156/table/ced.T.tgfb1_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ced.T.tgfb1_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.30_38dup</td><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu11_Leu13dup</td><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000660.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000660<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/63025222" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000651<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.241T&#x0003e;C</td><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr81His</td></tr><tr><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.652C&#x0003e;T</td><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg218Cys</td></tr><tr><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.653G&#x0003e;A</td><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg218His</td></tr><tr><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.664C&#x0003e;G</td><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His222Asp</td></tr><tr><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.673T&#x0003e;C</td><td headers="hd_h_ced.T.tgfb1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys225Arg</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Transforming growth factor beta-1 (TGF-&#x003b2;1) is synthesized as a large precursor molecule. TGF-&#x003b2;1 preprotein contains a signal peptide of 29 amino acids that is proteolytically cleaved. TGF-&#x003b2;1 is further cleaved after amino acid 278 to form latency-associated peptide (LAP) and active TGF-&#x003b2;1. LAP dimerizes with interchain disulfide links at Cys223 and Cys225. TGF-&#x003b2;1 can be secreted as an inactive small latent complex that consists of a mature TGF-&#x003b2;1 homodimer non-covalently associated with an LAP homodimer at LAP residues Ile<sup>53</sup>-Leu<sup>59</sup>. LAP shields the type II receptor binding sites in the mature TGF-&#x003b2;1. Most cells secrete TGF-&#x003b2;1 as a large latent complex (LLC) of TGF-&#x003b2;1/LAP covalently bound between Cys<sup>33</sup> in the LAP chains and latent TGFB-binding protein (LTBP). LTBPs facilitate TGF-&#x003b2;1 folding, secretion, and possibly targeting to the extracellular matrix. Activation of the LLC occurs via the N-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of LTBP binding to the extracellular matrix.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The majority of pathogenic variants in individuals with CED result in single amino-acid substitutions in the carboxy terminus of TGF-&#x003b2;1 latency-associated peptide (LAP). The substitutions are near the site of interchain disulfide bonds between the LAP homodimers. These pathogenic variants disrupt dimerization of LAP and binding to active TGF-&#x003b2;1 [<a class="bk_pop" href="#ced.REF.walton.2010.17029">Walton et al 2010</a>], leading to increased active TGF-&#x003b2;1 release from the cell. p.Arg218His mutated fibroblasts from individuals with CED showed increased active TGF-&#x003b2;1 in the cell media compared to normal fibroblasts [<a class="bk_pop" href="#ced.REF.saito.2001.11469">Saito &#x00026; Kinoshita 2001</a>]. In vitro analysis of p.Arg218Cys, p.His222Asp, and p.Cys225Arg mutated constructs also showed increased active TGF-&#x003b2;1 in the medium of transfected cells. In contrast, the p.Leu11_Leu13dup and p.Tyr81His pathogenic variants caused a decrease in the amount of TGF-&#x003b2;1 secreted. However, in a luciferase reporter assay specific for TGF-&#x003b2;1-induced transcriptional response, the mutated cells showed increased luciferase activity, suggesting intracellular activation of the receptor [<a class="bk_pop" href="#ced.REF.janssens.2003.7718">Janssens et al 2003</a>].</p></div><div id="ced.References"><h2 id="_ced_References_">References</h2><div id="ced.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ced.REF.ayyavoo.2014.3978">Ayyavoo A, Derraik JGB, Cutfield WS, Hofman PL. Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2014;<span class="ref-vol">99</span>:3978–82.</span> [<a href="/pubmed/25140400" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25140400</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.ba_.1999.401">Ba&#x0015f; F, Darendeliler F, Petorak I, Sadikoglu B, Bilir A, Bundak R, Saka N, Gunoz H. Deflazacort treatment in progressive diaphyseal dysplasia (Camurati-Engelmann disease). <span><span class="ref-journal">J Paediatr Child Health. </span>1999;<span class="ref-vol">35</span>:401–5.</span> [<a href="/pubmed/10457303" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10457303</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.camposxavier.2001.653">Campos-Xavier B, Saraiva JM, Savarirayan R, Verloes A, Feingold J, Faivre L, Munnich A, Le Merrer M, Cormier-Daire V. Phenotypic variability at the TGF-beta1 locus in Camurati-Engelmann disease. <span><span class="ref-journal">Hum Genet. </span>2001;<span class="ref-vol">109</span>:653–8.</span> [<a href="/pubmed/11810278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11810278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.carlson.2010.566">Carlson ML, Beatty CW, Neff BA, Link MJ, Driscoll CL. Skull base manifestations of Camurati-Engelmann disease. <span><span class="ref-journal">Arch Otolaryngol Head Neck Surg. </span>2010;<span class="ref-vol">136</span>:566–75.</span> [<a href="/pubmed/20566907" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20566907</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.castro.2005.398">Castro GR, Appenzeller S, Marques-Neto JF, Bertolo MB, Samara AM, Coimbra I. Camurati-Engelmann disease: failure of response to bisphosphonates: report of two cases. <span><span class="ref-journal">Clin Rheumatol. </span>2005;<span class="ref-vol">24</span>:398–401.</span> [<a href="/pubmed/15660289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15660289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.friedland.2000.160">Friedland DR, Wackym PA, Rhee JS, Finn MS. Cochlear implantation for auditory rehabilitation in Camurati-Engelmann disease. <span><span class="ref-journal">Ann Otol Rhinol Laryngol. </span>2000;<span class="ref-vol">109</span>:160–2.</span> [<a href="/pubmed/10685567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10685567</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.gulledge.1951.793">Gulledge WH, White JW. Englemann's disease (progressive diaphyseal hyperostosis); report of a case. <span><span class="ref-journal">J Bone Joint Surg Am. </span>1951;<span class="ref-vol">33-A</span>:793–7.</span> [<a href="/pubmed/14850520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14850520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.gupta.2005.399">Gupta S, Cheikh IE. Camurati-Engelmann disease in conjunction with hypogonadism. <span><span class="ref-journal">Endocr Pract. </span>2005;<span class="ref-vol">11</span>:399–407.</span> [<a href="/pubmed/16638728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16638728</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.hecht.2001.198">Hecht JT, Blanton SH, Broussard S, Scott A, Rhoades Hall C, Milunsky JM. Evidence for locus heterogeneity in the Camurati-Engelmann (DPD1) Syndrome. <span><span class="ref-journal">Clin Genet. </span>2001;<span class="ref-vol">59</span>:198–200.</span> [<a href="/pubmed/11260231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11260231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.herrera.2017.3489">Herrera S, Soriano R, Nogu&#x000e9;s X, G&#x000fc;erri-Fernandez R, Grinberg D, Garc&#x000ed;a-Giralt N, Mart&#x000ed;nez-Gil N, Castej&#x000f3;n S, Gonz&#x000e1;lez-Lizar&#x000e1;n A, Balcells S, Diez-Perez A. Discrepancy between bone density and bone material strength index in three siblings with Camurati-Engelmann disease. <span><span class="ref-journal">Osteoporos Int. </span>2017;<span class="ref-vol">28</span>:3489–93.</span> [<a href="/pubmed/28842728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28842728</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.inaoka.2001.680">Inaoka T, Shuke N, Sato J, Ishikawa Y, Takahashi K, Aburano T, Makita Y. Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease). <span><span class="ref-journal">Clin Nucl Med. </span>2001;<span class="ref-vol">26</span>:680–2.</span> [<a href="/pubmed/11452173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11452173</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.janssens.2000.273">Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, Lissens W, Van Maldergem L, Vanhoenacker F, Verbruggen L, Van Hul W. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. <span><span class="ref-journal">Nat Genet. </span>2000;<span class="ref-vol">26</span>:273–5.</span> [<a href="/pubmed/11062463" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11062463</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.janssens.2003.7718">Janssens K, ten Dijke P, Ralston SH, Bergmann C, Van Hul W. Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:7718–24.</span> [<a href="/pubmed/12493741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12493741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.janssens.2006.1">Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, Guanabens N, Migone N, Wientroub S, Divizia MT, Bergmann C, Bennett C, Simsek S, Melancon S, Cundy T, Van Hul W. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:1–11.</span> [<a href="/pmc/articles/PMC2564495/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564495</span></a>] [<a href="/pubmed/15894597" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15894597</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.kinoshita.2004.104">Kinoshita A, Fukumaki Y, Shirahama S, Miyahara A, Nishimura G, Haga N, Namba A, Ueda H, Hayashi H, Ikegawa S, Seidel J, Niikawa N, Yoshiura K. TGFB1 mutations in four new families with Camurati-Engelmann disease: Confirmation of independently arising LAP-domain-specific mutations. <span><span class="ref-journal">Am J Med Genet. </span>2004;<span class="ref-vol">127A</span>:104–7.</span> [<a href="/pubmed/15103729" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15103729</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.kinoshita.2000.19">Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Nishimura G, Fukushima Y, Nakagomi T, Saito H, Sugimoto T, Kamegaya M, Hisa K, Murray JC, Taniguchi N, Niikawa N, Yoshiura K. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. <span><span class="ref-journal">Nat Genet. </span>2000;<span class="ref-vol">26</span>:19–20.</span> [<a href="/pubmed/10973241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10973241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.lindstrom.1974.504">Lindstrom JA. Diaphyseal dysplasia (Engelmann) treated with corticosteroids. <span><span class="ref-journal">Birth Defects Orig Artic Ser. </span>1974;<span class="ref-vol">10</span>:504–7.</span> [<a href="/pubmed/4461085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4461085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.makita.2000.153">Makita Y, Nishimura G, Ikegawa S, Ishii T, Ito Y, Okuno A. Intrafamilial phenotypic variability in Engelmann disease (ED): are ED and Ribbing disease the same entity? <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">91</span>:153–6.</span> [<a href="/pubmed/10748417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10748417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.mumm.2001.593">Mumm SR, Obrecht S, Podgornik MN, Whyte MP. Camurati-Engelmann disease: new mutations in the latency-associated peptide of the transforming growth factor B-1 gene. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69S</span>:593.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.neuhauser.1948.11">Neuhauser EBD, Schwachman H, Wittenborg M, Cohen J. Progressive diaphyseal dysplasia. <span><span class="ref-journal">Radiology. </span>1948;<span class="ref-vol">51</span>:11–22.</span> [<a href="/pubmed/18869144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18869144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.ozt_rkmen.2011.58">Ozt&#x000fc;rkmen Y, Karamehmeto&#x0011f;lu M. Ribbing disease: a case report and literature review. <span><span class="ref-journal">Acta Orthop Traumatol Turc. </span>2011;<span class="ref-vol">45</span>:58–65.</span> [<a href="/pubmed/21478664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21478664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.popiela.2015">Popiela M, Austin M. Bilateral papilloedema in Camurati-Engelmann disease. BMJ Case Rep. 2015. Aug 18;2015. [<a href="/pmc/articles/PMC4550960/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4550960</span></a>] [<a href="/pubmed/26286906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26286906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.saito.2001.11469">Saito T, Kinoshita A. Yoshiura Ki, Makita Y, Wakui K, Honke K, Niikawa N, Taniguchi N. Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1. <span><span class="ref-journal">J Biol Chem. </span>2001;<span class="ref-vol">276</span>:11469–72.</span> [<a href="/pubmed/11278244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11278244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.simsekkiper.2014.2667">Simsek-Kiper PO, Dikoglu E, Campos-Xavier B, Utine GE, Bonafe L, Unger S, Boduroglu K, Superti-Furga A. Positive effects of an angiotensin II type 1 receptor antagonist in Camurati-Engelmann disease: a single case observation. <span><span class="ref-journal">Am J Med Genet A. </span>2014;<span class="ref-vol">164A</span>:2667–71.</span> [<a href="/pubmed/25099136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25099136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.trombetti.2012.75">Trombetti A, Cortes F, Kaelin A, Morris M, Rizzoli R. Intranasal calcitonin reducing bone pain in a patient with Camurati-Engelmann disease. <span><span class="ref-journal">Scand J Rheumatol. </span>2012;<span class="ref-vol">41</span>:75–7.</span> [<a href="/pubmed/22044122" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22044122</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.verbruggen.1985.809">Verbruggen LA, Bossuyt A, Schreuer R, Somers G. Clinical and scintigraphic evaluation of corticosteroid treatment in a case of progressive diaphyseal dysplasia. <span><span class="ref-journal">J Rheumatol. </span>1985;<span class="ref-vol">12</span>:809–13.</span> [<a href="/pubmed/4057207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4057207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.wallace.2004.235">Wallace SE, Lachman RS, Mekikian PB, Bui KK, Wilcox WR. Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati-Engelmann disease): report of a four-generation pedigree, identification of a mutation in TGFB1, and review. <span><span class="ref-journal">Am J Med Genet. </span>2004;<span class="ref-vol">129A</span>:235–47.</span> [<a href="/pubmed/15326622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15326622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.wong.2017.555">Wong T, Herschman Y, Patel NV, Patel T, Hanft S. Repeat Intracranial Expansion After Skull Regrowth in Hyperostotic Disease: Technical Note. <span><span class="ref-journal">World Neurosurg. </span>2017;<span class="ref-vol">102</span>:555–60.</span> [<a href="/pubmed/28137547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28137547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.walton.2010.17029">Walton KL, Makanji Y, Chen J, Wilce MC, Chan KL, Robertson DM, Harrison CA. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-<em>&#x003b2;</em>1 complex. <span><span class="ref-journal">J Biol Chem. </span>2010;<span class="ref-vol">285</span>:17029–37.</span> [<a href="/pmc/articles/PMC2878044/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2878044</span></a>] [<a href="/pubmed/20308061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20308061</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ced.REF.yuldashev.2017.109">Yuldashev AJ, Shin CH, Kim YS, Jang WY, Park MS, Chae JH, Yoo WJ, Choi IH, Kim OH, Cho TJ. Orthopedic manifestations of type I Camurati-Engelmann disease. <span><span class="ref-journal">Clin Orthop Surg. </span>2017;<span class="ref-vol">9</span>:109–15.</span> [<a href="/pmc/articles/PMC5334020/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5334020</span></a>] [<a href="/pubmed/28261436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28261436</span></a>]</div></li></ul></div></div><div id="ced.Chapter_Notes"><h2 id="_ced_Chapter_Notes_">Chapter Notes</h2><div id="ced.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 October 2017 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 March 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 December 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 June 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 August 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 June 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>18 March 2004 (sw) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1156</span><span class="label">PMID: <a href="/pubmed/20301335" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301335</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/campo-dysp/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/canavan/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1156&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1156/?report=reader">PubReader</a></li><li><a href="/books/NBK1156/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1156" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1156" style="display:none" title="Cite this Page"><div class="bk_tt">Wallace SE, Wilcox WR. Camurati-Engelmann Disease. 2004 Jun 25 [Updated 2017 Oct 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1156/pdf/Bookshelf_NBK1156.pdf">PDF version of this page</a> (453K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ced.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ced.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#ced.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ced.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ced.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ced.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ced.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ced.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ced.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ced.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ced.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ced.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7040[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TGFB1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1156+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1499690" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1499690" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1499690" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1499690" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15326622" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati-Engelmann disease): report of a four-generation pedigree, identification of a mutation in TGFB1, and review.</a><span class="source">[Am J Med Genet A. 2004]</span><div class="brieflinkpop offscreen_noflow">Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati-Engelmann disease): report of a four-generation pedigree, identification of a mutation in TGFB1, and review.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wallace SE, Lachman RS, Mekikian PB, Bui KK, Wilcox WR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2004 Sep 1; 129A(3):235-47. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301306" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CLCN7</i>-Related Osteopetrosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CLCN7</i>-Related Osteopetrosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sobacchi C, Villa A, Schulz A, Kornak U. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301588" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Muenke Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Muenke Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kruszka P, Addissie YA, Agochukwu NB, Doherty ES, Muenke M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301634" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Craniometaphyseal Dysplasia, Autosomal Dominant</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Craniometaphyseal Dysplasia, Autosomal Dominant<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Reichenberger E, Chen IP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301298" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Darras BT, Urion DK, Ghosh PS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301335" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301335" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041022dd21425a258c6c3b">Camurati-Engelmann Disease - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Camurati-Engelmann Disease - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:42:58-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE894EF1E040A5210000000002D70150&amp;ncbi_session=CE894EF1E0410211_0727SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1156%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1156&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1156/&amp;ncbi_pagename=Camurati-Engelmann Disease - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE894EF1E0410211_0727SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>